Hepatitis B market to be contested by 3 pharmaceutical firms
Published: 2006-08-02 06:59:00
Updated: 2006-08-02 06:59:00
Pharmaceutical business sources that domestic hepatitis B market will emerge as an arena of tripartite competition GlaxoSmithKline's Zeffix (lamivudine) and Hepsera (adefovir), Bukwang Pharm's Levovir (clevudine) and BMS Korea's BARACLUDE (entecavir).
Levovir, the first-domestically-made medi...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
